- Home
- DOCU vs VTRS Comparison
DOCU vs VTRS Comparison
Compare DOCU & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCU
- VTRS
- Stock Information
- Founded
- DOCU 2003
- VTRS 1961
- Country
- DOCU United States
- VTRS United States
- Employees
- DOCU N/A
- VTRS N/A
- Industry
- DOCU EDP Services
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- DOCU Technology
- VTRS Health Care
- Exchange
- DOCU Nasdaq
- VTRS Nasdaq
- Market Cap
- DOCU 14.5B
- VTRS 11.8B
- IPO Year
- DOCU 2018
- VTRS N/A
- Fundamental
- Price
- DOCU $79.86
- VTRS $10.50
- Analyst Decision
- DOCU Hold
- VTRS Hold
- Analyst Count
- DOCU 16
- VTRS 5
- Target Price
- DOCU $95.31
- VTRS $10.40
- AVG Volume (30 Days)
- DOCU 3.0M
- VTRS 9.3M
- Earning Date
- DOCU 09-04-2025
- VTRS 11-06-2025
- Dividend Yield
- DOCU N/A
- VTRS 4.57%
- EPS Growth
- DOCU N/A
- VTRS N/A
- EPS
- DOCU 1.33
- VTRS N/A
- Revenue
- DOCU $3,095,362,000.00
- VTRS $14,115,700,000.00
- Revenue This Year
- DOCU $8.31
- VTRS N/A
- Revenue Next Year
- DOCU $6.61
- VTRS $1.66
- P/E Ratio
- DOCU $59.88
- VTRS N/A
- Revenue Growth
- DOCU 8.29
- VTRS N/A
- 52 Week Low
- DOCU $54.32
- VTRS $6.85
- 52 Week High
- DOCU $107.86
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- DOCU 62.22
- VTRS 61.05
- Support Level
- DOCU $73.34
- VTRS $10.29
- Resistance Level
- DOCU $76.64
- VTRS $10.61
- Average True Range (ATR)
- DOCU 2.20
- VTRS 0.19
- MACD
- DOCU 0.92
- VTRS -0.05
- Stochastic Oscillator
- DOCU 76.08
- VTRS 45.76
About DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.